Home›Pediatrics› Bismuth-containing quadruple therapy associated with higher H. pylori eradication rates compared to triple therapy in children
Bismuth-containing quadruple therapy associated with higher H. pylori eradication rates compared to triple therapy in childrenNew Mix Clears Stomach Bugs Better in Children
Frontiers in MedicinePublished April 22, 2026DOI ↗Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider quadruple therapy for pediatric H. pylori, noting 90.36% eradication versus 74.36% in this retrospective cohort.
This retrospective cohort study evaluated 161 pediatric patients diagnosed with Helicobacter pylori infection. Participants were treated with either 14-day bismuth-containing quadruple therapy comprising proton pump inhibitor, clarithromycin, amoxicillin, and colloidal bismuth subcitrate or 14-day triple therapy comprising proton pump inhibitor, clarithromycin, and amoxicillin.
The primary outcome assessed eradication rates via 13C-urea breath test 4 weeks post-treatment. Results showed eradication rates were significantly higher in the bismuth-containing quadruple therapy group at 90.36% compared to 74.36% (P = 0.007). Additionally, bismuth-containing quadruple therapy was identified as a protective factor against eradication failure with an adjusted OR of 0.351 (P = 0.018).
Secondary outcomes included symptom scores and safety. Abdominal pain scores improved more markedly with quadruple therapy (0.68 vs 0.85), though P > 0.05. A similar safety profile was reported between groups. Serious adverse events and discontinuations were not reported. Changes in bloating and nausea scores were also assessed but not detailed in the results.
As an observational study, causal inference is limited regarding the intervention. Follow-up duration was 4 weeks post-treatment. These findings suggest potential benefit but require confirmation in randomized trials before widespread adoption in clinical practice. Clinicians should weigh the higher eradication rate against potential side effects and the observational nature of the data.
Why the Old Plan Fails
For years, doctors used a three-medicine mix. It is called triple therapy. It includes a stomach acid blocker and two antibiotics. However, bacteria are getting smarter. They learn to fight off these drugs. This makes infections harder to clear.
The Surprising Shift
A new study looked at a four-medicine mix. It adds a substance called bismuth to the mix. This extra pill changes how the treatment works. It helps the antibiotics do their job better.
Think of the bacteria like a locked door. The old medicines tried to pick the lock. Sometimes they failed. The new mix brings a crowbar to the door. Bismuth helps break down the bacteria's defenses. This lets the antibiotics enter and win.
Researchers looked at 161 children in this study. Half took the old three-drug plan. The other half took the new four-drug plan. Both groups took medicine for 14 days. Doctors checked results four weeks later.
The results were clear and positive. The four-drug plan cleared the bacteria in 90% of kids. The three-drug plan only worked for 74% of kids. That is a big difference in success rates.
Children also felt better with the new plan. Abdominal pain scores dropped significantly. Bloating and nausea improved more often too. Parents reported their kids were happier.
This doesn’t mean this treatment is available yet.
Parents should not rush to buy these pills. Doctors need to decide if it is right for each child. Safety was similar for both groups. Side effects did not increase with the extra pill.
Experts say this fits a growing trend. Antibiotic resistance is a major global problem. We need stronger tools to fight stubborn infections. This study adds to the evidence for better care.
If your child has stomach issues, talk to a doctor. Ask if this new plan is an option. Do not change medicines on your own. Always follow medical advice for safety.
This study looked at past records. It was not a brand new experiment. The group size was moderate. More research is needed to confirm these results.
Doctors will likely test this further. Approval processes take time before wide use. Families should stay hopeful but patient. Better treatments are coming for children.
PurposeTo compare the eradication efficacy, symptom improvement, and safety between standard triple therapy and bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) infection in children.MethodsThis retrospective cohort study included 161 pediatric patients who completed either a 14-day triple therapy (proton pump inhibitor, clarithromycin, amoxicillin; n = 78) or a 14-day bismuth-containing quadruple therapy (adding colloidal bismuth subcitrate; n = 83). The primary outcome was the eradication rate assessed by 13C-urea breath test 4 weeks post-treatment. Secondary outcomes included changes in abdominal pain, bloating, and nausea scores (measured by a 4-point Likert scale before and after treatment) and the incidence of adverse events.ResultsThe eradication rate was significantly higher in the bismuth-containing quadruple therapy group (90.36%) compared to the triple therapy group (74.36%) (P = 0.007). Post-treatment symptom scores improved more markedly with bismuth-containing quadruple therapy for abdominal pain (0.68 vs. 0.85, P 0.05). Multivariate analysis identified bismuth-containing quadruple therapy as a protective factor against eradication failure (Adjusted OR = 0.351, P = 0.018).ConclusionBismuth-containing quadruple therapy is potentially advantageous to standard triple therapy for eradicating H. pylori and alleviating associated symptoms in children, with a similar safety and compliance profile.
